Test Price
1,100 AED✅ Home Collection Available
BCR-ABL Quantitative MRD Monitor Test in UAE | 1100 AED | DHA Licensed Facility
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing with Real-Time Quantitative PCR (qPCR) and Whole Genome Sequencing (WGS).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM; refrigerated transport mandatory – DO NOT FREEZE.
- Clinical Guidance: Telephonic post-test result interpretation by a DHA-licensed Consultant Medical Geneticist.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The BCR-ABL Quantitative MRD Monitor employs ultra-sensitive molecular methods to measure minimal residual disease (MRD) in patients with Philadelphia chromosome-positive leukemias, including chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL). The assay quantifies the BCR-ABL1 fusion transcript relative to a control gene using real-time quantitative PCR (qPCR), with orthogonal confirmation by whole genome sequencing (WGS). This dual-methodology approach delivers sensitivity down to MR4.5 (0.0032% International Scale), enabling early detection of molecular relapse and precise titration of tyrosine kinase inhibitor therapy. Serial monitoring provides a dynamic molecular trajectory that informs treatment duration, drug switching, and allogeneic transplant timing.
| Feature | Our Test (Precision / Method / Speed) | Closest Alternative |
|---|---|---|
| Precision | Sensitivity down to MR4.5 (0.0032% IS) via qPCR validated by WGS | Standard RT-PCR, sensitivity often limited to MR3.0 |
| Method | Real-Time Quantitative PCR (qPCR) + Whole Genome Sequencing (WGS) | qPCR alone or digital PCR without orthogonal confirmation |
| Speed | Samples collected Mon/Wed/Fri by 9 AM; reports delivered Tue/Thu/Sat | Often 5–7 working days |
Physician Insight & Safety Protocols
“As a Consultant in Medical Genetics, I view BCR-ABL MRD monitoring as a molecular compass that guides precision oncology. The quantitative trajectory of the fusion transcript over time provides far more clinical insight than any single value. I always remind patients that molecular response is a dynamic process—consistent monitoring combined with expert interpretation forms the backbone of successful long-term management in Philadelphia-positive leukemias. Results must always be evaluated in the context of the full clinical picture and prior treatment history.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notice
Medication Warning: Do not discontinue or alter prescribed tyrosine kinase inhibitor therapy without consulting your treating hematologist. Changing your medication regimen based solely on test results without medical supervision can lead to disease progression or life-threatening complications.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Inability to provide a completed MRD Requisition Form (Form 22) with prior molecular and treatment history; sample frozen instead of refrigerated; gross haemolysis or clotting in the EDTA tube.
- Emergency Red Flags: If you experience sudden fever, uncontrolled bleeding, severe bone pain, or new neurological symptoms alongside rising BCR-ABL levels, seek immediate emergency care at the nearest hospital.
- Pre-Collection Note: Bone marrow aspiration must be performed by an authorised clinician in a hospital setting. For routine monitoring, peripheral whole blood collected in EDTA (Lavender Top) tube, refrigerated at 2–8°C, is standard.
Patient FAQ & Clinical Guidance
1. What is the purpose of BCR-ABL Quantitative MRD monitoring?
BCR-ABL quantitative MRD monitoring precisely measures the level of residual leukemia cells carrying the Philadelphia chromosome translocation. The assay quantifies the BCR-ABL1 fusion transcript on the International Scale (IS), allowing oncologists to assess molecular remission depth — major molecular response (MMR/MR3), MR4.0, or MR4.5. Regular monitoring guides tyrosine kinase inhibitor dosing, signals emerging drug resistance, and informs the optimal timing for allogeneic stem cell transplantation in CML and Ph+ ALL.
2. How should I prepare for this test?
A completed MRD Requisition Form (Form 22) with your prior molecular results and current medication list is mandatory. No fasting is required. For home collection, our phlebotomist will bring insulated cold packs to maintain sample integrity at 2–8°C during transport. Ensure the EDTA (Lavender Top) tube is filled to the correct volume and gently inverted to prevent clotting. If a bone marrow sample is required, our team will coordinate directly with your hospital for a scheduled procedure.
3. What do the results mean and what should I do next?
A sustained reduction in BCR-ABL transcript levels indicates a favourable molecular response, while a significant rise may signal resistance, non-adherence to therapy, or impending relapse. Results are reported on the International Scale (IS) as a percentage relative to a standardized baseline. A 3-log reduction (MR3) or deeper is generally associated with improved long-term outcomes. Always discuss your report with your hematologist or medical geneticist before making any treatment decisions. Our telephonic clinical guidance service provides immediate, personalized context for your results to bridge the gap between laboratory data and clinical action.
4. How often should MRD monitoring be performed?
For patients with CML, international guidelines recommend BCR-ABL monitoring every 3 months once molecular response is established, and more frequently (every 1–2 months) during the early treatment phase or when switching therapies. For Ph+ ALL, monitoring is typically aligned with treatment cycles and post-transplant surveillance protocols. Your physician will determine the optimal schedule based on your molecular kinetics and clinical risk factors.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All patient data, molecular results, and clinical records are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks ensure that your genetic and health information is collected, stored, and shared under strict confidentiality, consent, and security protocols. Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all molecular analyses are conducted with full patient awareness and under accredited medical supervision. DNA Labs UAE maintains ISO 9001:2015 certification and operates under DHA Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | BCR-ABL Quantitative MRD Monitor |
| Price (AED) | 1,100 AED |
| Turnaround Time | 2–3 working days (samples collected Mon/Wed/Fri by 9 AM; reports delivered Tue/Thu/Sat) |
| Sample Type / Matrix | Peripheral whole blood (EDTA Lavender Top) — refrigerated 2–8°C, DO NOT FREEZE; bone marrow aspirate (hospital procedure only) |
| Methodology Used | Real-Time Quantitative PCR (qPCR) + Whole Genome Sequencing (WGS) |
| ICD-10-CM Code | C92.1 (Chronic myeloid leukemia, BCR/ABL-positive); C91.0 (Ph+ acute lymphoblastic leukemia) |
| LOINC Code | 93923-2 (BCR-ABL1 transcript [Ratio] in Blood by NAA with probe detection) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians